Home > Insider Trading > Filing (0000899243-16-013608)

Filing Details

Accession Number:: 0000899243-16-013608
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-02-17 18:45:20
Reporting Period:: 2016-02-17

Filing Date:: 2016-02-17
Accepted Time:: 2016-02-17 18:45:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1445283	Proteostasis Therapeutics Inc.	PTI	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1013469	W John Littlechild	C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	No	No	Yes	No
1013473	H James Cavanaugh	C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	No	No	Yes	No
1013603	R Harold Werner	C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	No	No	Yes	No
1262326	Christopher Mirabelli	C/O Healthcare Ventures Llc, 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	Yes	No	Yes	No
1262327	Augustine Lawlor	C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	No	No	Yes	No
1358990	Healthcare Ventures Viii, L.p.	C/O Healthcare Ventures Llc, 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	No	No	Yes	No
1358991	Healthcare Partners Viii, L.p.	C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	No	No	Yes	No
1358992	Healthcare Partners Viii, Llc	C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-02-17	1,774,295	$0.00	1,774,295	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-02-17	375,000	$8.00	2,149,295	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Redeemable Preferred Stock	Disposition	2016-02-17	11,600,000	$0.00	1,559,707	$0.00
Common Stock	Series B Convertible Redeemable Preferred Stock	Disposition	2016-02-17	2,319,750	$0.00	214,588	$0.00
Series A Preferred Stock	Series A Convertible Preferred Warrant (Right to Buy)	Disposition	2016-02-17	160,000	$0.00	160,000	$1.00
Common Stock	Common Stock Warrant (Right to Buy)	Acquisiton	2016-02-17	14,800	$0.00	14,800	$10.81

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect
0	2008-07-08	2018-07-08	No	4	J	Indirect
14,800	2008-07-08	2018-07-08	No	4	J	Indirect

Footnotes

This transaction represents the total number of shares of Common Stock of the Issuer (the "Issuer Common Stock") received upon the conversion of the Issuer's Series A Convertible Redeemable Preferred Stock (the "Series A Shares"), the payment of accrued dividends on the Series A Shares and the conversion of the Issuer's Series B Convertible Redeemable Preferred Stock ( collectively, the "Preferred Shares").
The securities are held of record by HealthCare Ventures VIII, L.P. ("HCVVIII"). HealthCare Partners VIII, L.P. ("HCPVIII") is the General Partner of HCVVIII and HealthCare Partners VIII, LLC (the "LLC") is the General Partner of HCPVIII. Each of James Cavanaugh, Harold Werner, John Littlechild, Christopher Mirabelli and Augustine Lawlor are the managing directors of the LLC and exercise shared voting and investment power with respect to the shares owned by HCVVIII. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein. Dr. Mirabelli is also a director of the issuer.
These securities were purchased in the initial public offering of the Issuer.
The Preferred Shares automatically converted into Issuer Common Stock on a 10.8102-to-1 basis upon the closing of the initial public offering of the Issuer without payment or further consideration. The Preferred Shares were convertible at any time at the election of the Reporting Person and had no expiration date.
These securities include shares of Issuer Common Stock received as payment for accrued dividends on the Series A Shares.
This transaction represents a deemed disposition of warrants to purchase Series A Shares and a deemed acquisition of warrants to purchase shares of Issuer Common Stock on a 10.8102-to-1 basis, which occurred automatically upon the closing of the initial public offering of the Issuer without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants.